Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast
Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast
SAN FRANCISCO – (Business Wire) – August 6, 2024 – Tivic Health Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a corporate update that will highlight the importance of Tivic's vagus nerve research program and its market potential. The company invites questions to be submitted to ir@tivichealth.com by August 11, 2024.
旧金山-(商业线)2024年8月6日-Tivic Health Systems,Inc.(“Tivic Health”,纳斯达克:TIVC)是一家开发和商业化生物电疗技术的医疗科技公司,今日宣布将于美国时间8月14日星期三下午1:30点/4:30 pm Et通过预录音会议通话和网络直播公布其2024年Q2财务业绩和企业更新。鼓励现有股东、有兴趣的个人和未来投资者参加网络直播以听取公司高管提供企业更新,重点突出Tivic的迷走神经研究项目及其市场潜力。公司邀请通过ir@tivichealth.com提交问题截止日期为2024年8月11日。
Teleconference Details:
电话会议详细信息:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 316159
免费电话:888-506-0062
国际电话:973-528-0011
参与者接入代码:316159
Webcast Link
网络直播链接
About Tivic Health
关于Tivic Health
Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health's technology platforms leverage stimulation of the trigeminal, sympathetic, and vagus nerve structures. Tivic Health's non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health's first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit @TivicHealth
Tivic Health是一家商业化健康科技公司,推进生物电医学领域。 Tivic Health的技术平台利用三叉神经,交感神经和迷走神经结构的刺激。 Tivic Health针对慢性炎症性健康状况的非侵入式和有针对性的治疗方法为消费者和提供者提供了无需药物的治疗解决方案,具有高安全性、低风险和广泛应用的特点。 Tivic Health的第一个商业产品ClearUP是一种FDA批准、获奖的手持生物电气剑突设备。 ClearUP经过临床验证,得到医生的推荐,可通过在线零售商和商业分销商获得。欲了解更多信息,请访问@TivicHealth
Forward-Looking Statements
前瞻性声明
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading "Risk Factors"; as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
本新闻稿可能包含“前瞻性声明”,受到重大风险和不确定性的影响。本新闻稿中除了历史事实之外的所有陈述都是前瞻性陈述。本新闻稿中包含的前瞻性陈述可以通过使用诸如“预测”、“相信”、“思考”、“可能”、估计”、“期望”、“意图”、“寻找”、“可能”、“计划”、“潜在的”、“预测”、“项目”、“目标”、“目的”、“应该”、“将”、“会”等词语或其他类似的表达式来识别,虽然不是所有的前瞻性陈述都包含这些词。前瞻性陈述基于Tivic Health Systems, Inc.的当前预期,并且存在难以预测的固有不确定性、风险和假设。此外,某些前瞻性陈述是基于对未来事件的假设,这些假设可能不会被证明准确。由于各种因素的影响,实际结果可能会与任何前瞻性陈述中所包含的结果有所不同。因此,您应谨慎使用这些先前的陈述。有关涉及公司的风险和不确定性以及其他重要因素的讨论,请参见Tivic Health向证券交易委员会提交的文件,包括于2024年3月29日提交的截至2023年12月31日结束的年度报告10-k,其中根据“风险因素”的标题;以及公司随后向证券交易委员会提交的文件。在本新闻稿中包含的前瞻性声明是截至本日期,Tivic Health Systems, Inc.除根据适用法律规定外,不承担更新此类信息的义务。
Media Contact:
媒体联系人:
Morgan Luke
Morgan Luke
Morgan.Luke@tivichealth.com
Morgan.Luke@tivichealth.com
Investor Contact:
投资者联系人:
Hanover International, Inc.
Hanover International, Inc.
ir@tivichealth.com
ir@tivichealth.com